...
首页> 外文期刊>Clinical therapeutics >Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for or
【24h】

Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for or

机译:随机,开放标签,平行组,多中心研究,静脉输注加替沙星与口服降压加替沙星对比静脉注射头孢曲松(有或没有红霉素或克拉霉素),可选择或不选择口服加替沙星的疗效和耐受性

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Empiric therapy for community-acquired pneumonia (CAP) requires the use of antibiotics with activity against a broad spectrum of respiratory pathogens and suitable pharmacokinetic properties to simplify IV-to-oral step-down therapy switches. OBJECTIVE: The aim of this study was to compare the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin with a standard regimen of IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin in patients with mild to moderate CAP requiring hospitalization. METHODS: In a randomized, open-label, parallel-group, multicenter study, adults with CAP received 7 to 14 days of treatment with either IV gatifloxacin 400 mg QD with the stepdown option or IV ceftriaxone 1 or 2 g QD (with or without erythromycin 0.5 or 1 g QID or clarithromycin 500 mg BID) with the stepdown option. RESULTS: One hundred seventy adults with CAP were included in the study. IV gatifloxacin was stepped down to oral gatifloxacin in 90.6% (7785) of patients; IV ceftriaxone was stepped down to oral clarithromycin in 87.1% (7485) of patients. Among clinically evaluable patients (n = 153), cure rates at 1 to 3 days after treatment were 97.4% in the gatifloxacin group (7476) and 90.9% in the ceftriaxone group (7077), with a 95% CI for the difference (-3.7% to 19.1%) indicating statistical equivalence. In patients in whom pathogens were isolated from pretreatment sputum cultures, bacteriologic eradication rates were 100.0% (2929) and 90.9% (3033), respectively. Both regimens were well tolerated; treatment-related adverse events occurred in 27.1% (2385) and 21.2% (1885) of patients, respectively. CONCLUSIONS: In the population studied, treatment with IV gatifloxacin with an option for oral stepdown gatifloxacin was as effective for achieving clinical cure as IV ceftriaxone (with or without concomitant IV erythromycin or clarithromycin) with an option for oral stepdown clarithromycin. Both regimens were welltolerated.
机译:背景:针对社区获得性肺炎(CAP)的经验疗法需要使用对广泛的呼吸道病原体具有活性的抗生素以及合适的药代动力学特性,以简化静脉内-口服降压疗法的转换。目的:本研究的目的是比较静脉加替沙星与口服降级加替沙星与静脉注射头孢曲松标准方案(有或没有红霉素或克拉霉素)与口服降压克拉霉素治疗轻度患者的疗效和耐受性中度CAP需要住院。方法:在一项随机,开放标签,平行组,多中心研究中,患有CAP的成年人接受400毫克加替沙星400毫克QD联合降压治疗或静脉注射头孢曲松1或2克QD治疗(有或没有)红霉素0.5或1 g QID或克拉霉素500 mg BID),并带有降压选项。结果:一百七十名患有CAP的成年人被纳入研究。 90.6%(7785)的患者将静脉注射加替沙星降为口服加替沙星;在87.1%(7485)的患者中,静脉注射头孢曲松降为口服克拉霉素。在临床上可评估的患者(n = 153)中,加替沙星组(7476)和头孢曲松组(7077)在治疗后1至3天的治愈率分别为97.4%和90.9%,差异为95%(- 3.7%至19.1%)表示具有统计意义。从预处理痰培养物中分离出病原体的患者中,细菌根除率分别为100.0%(2929)和90.9%(3033)。两种方案的耐受性都很好。与治疗相关的不良事件分别发生在27.1%(2385)和21.2%(1885)的患者中。结论:在接受研究的人群中,IV加替沙星与口服降级加替沙星的选择治疗与IV头孢曲松(有或无IV红霉素或克拉霉素)以及可选择口服降级克拉霉素的治疗一样,可以有效地实现临床治愈。两种方案均耐受良好。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号